Treatment of Nonvariceal Upper Gastrointestinal Bleeding.

Acid-suppressive therapy is beneficial in the brass of UGB. It reduces the absolute frequency of rebleeding, the need for surgical operation, introduction requirements, and the fundamental measure of medical building stay. To date, no pharmacologic aid has demonstrated a decrease in the impermanency rates of patients with UGB. An optimal acid-suppressive regimen has not yet been clearly established.
Since the substance and approving of this medium, a musical composition by Hsu et al. was published comparing i.v. pantoprazole (40 mg tablet dose followed by 40 mg every 12 hours) with i.v. ranitidine (50 mg tablet dose followed by 50 mg every 8 hours) in 102 patients who had received prior endoscopic artistic style. Of the 52 patients receiving pantoprazole, bleeding recurred in just 2 patients (4%), compared with 8 (16%) of those in the ranitidine unit ( n = 50) ( p = 0.04). Also, i.v. esomeprazole (Nexium, AstraZeneca) and lansoprazole (Prevacid, TAP Pharmaceutical Products) have become available in the United States.